Infusion services remain a vital component of medical treatment for patients across the nation, each area containing its own complexities that create challenges for coders and compliance professionals alike. In July 2023, the FDA gave the green light to Beyfortus™ (nirsevimab-alip) for infants under eight months old encountering their first respiratory syncytial virus (RSV) season and certain high-risk children aged 8–19 months entering their second RSV season. While nirsevimab acts as a preventative measure against illness, it is crucial to understand that the FDA categorizes it as a drug rather than a conventional vaccine. This classification has triggered uncertainty among medical coders regarding the appropriate CPT® code for reporting administration and how to account for counseling efforts, particularly in pediatric settings. Let’s analyze more of the specific details for accurate understanding and successful outcomes throughout 2024 and beyond.
Initially, providers were guided to use CPT code 96372 for administering nirsevimab. However, in September 2023, the CPT Editorial Panel authorized immunization administration codes 96380 and 96381, effective from October 6, 2023. Understand that these codes are not yet included in the 2024 CPT Manual but are slated for inclusion in the 2025 edition, positioned after code 96377. This update streamlines the coding process, ensuring accurate reporting of nirsevimab administrations.
Unlike traditional vaccines, the administration of nirsevimab is not reported with the ICD-10-CM code Z23 (Encounter for immunization). Coders should understand that this diagnosis code is specific to immunization related to vaccines.
Instead, coders should refer to Z29.11 Encounter for prophylactic immunotherapy for respiratory syncytial virus (RSV). Utilizing the correct diagnosis code is pivotal for billing accuracy, claims processing, and data integrity. Moreover, when administering nirsevimab to patients with high-risk conditions, it’s essential to append code Z29.11 alongside the relevant ICD-10-CM code corresponding to each patient’s specific high-risk condition.
| Code | Description |
| 90380 | Respiratory syncytial virus, monoclonal antibody, seasonal dose; 0.5 mL dosage, for intramuscular use |
| 90381 | Respiratory syncytial virus, monoclonal antibody, seasonal dose; 1 mL dosage, for intramuscular use |
www.ama-assn.org/system/files/vaccine-long-descriptors.pdf
When should the above codes be reported? Assign either CPT code 90380 or 90381 on all claims for Beyfortus (nirsevimab-alip). Understand that these codes are specific to passive immunization for pediatric seasonal dose for RSVb and are differentiated by dose description of 0.5-mL dose and 1-mL. For clarity, report as one unit of 90380 when a 0.5-mL dose is administered. Report as one unit of 90381 when a 1-mL dose is administered and submit two units of 90381 when a 2-mL dose is administered.
It’s worth noting that the monoclonal antibody palivizumab carries the product code 90378 and is not to be reported with administration codes 96380 or 96381. The guidance provided by the AMA instructs healthcare providers to utilize the new CPT codes specifically designated for the administration of respiratory syncytial virus monoclonal antibody seasonal doses, outlined as 90380 and 90381. For a more comprehensive discussion on coding pertaining to the administration of vaccines or toxoids, refer to Chapter 19.
These are not all the tips necessary for successful infusion and injection therapy coding. Secure your copy of the 2024 Coding Essentials for Infusion & Injection Therapy Services eBook by March 29, 2024, and enjoy a $50 discount!
To take advantage of this offer, enter promo code 50EPINF24 at checkout. Don’t delay, order today!
Additional references and guidance may be found at the website of American Academy of Pediatrics:
The role of physician advisors has evolved into an absolute necessity in hospitals of all sizes around the country. As the healthcare landscape rapidly evolves,
As I continue to focus on documentation, this week I am turning my attention to a frequently misunderstood Medicare rule: the Three-Day Payment Window. This
Please log in to your account to comment on this article.
Only ICD10monitor delivers what you need: updates on must-know changes associated with the FY26 IPPS, including new ICD-10-CM/PCS codes, CCs/MCCs, and MS-DRGs, plus insights, analysis and answers to your questions from two of the country’s most respected subject matter experts.
This third session in our 2026 IPPS Masterclass will feature a review of FY26 changes to the MS-DRG methodology and new technology add-on payments (NTAPs), presented by nationally recognized ICD-10 coding expert Christine Geiger, MA, RHIA, CCS, CRC, with bonus insights and analysis from Dr. James Kennedy.
This second session in our 2026 IPPS Masterclass will feature a review the FY26 changes to ICD-10-PCS codes. This information will be presented by nationally recognized ICD-10 coding expert Christine Geiger, MA, RHIA, CCS, CRC, with bonus insights and analysis from Dr. James Kennedy.
This first session in our 2026 IPPS Masterclass will feature an in-depth explanation of FY26 changes to ICD-10-CM codes and guidelines, CCs/MCCs, and revisions to the MCE, presented by presented by nationally recognized ICD-10 coding expert Christine Geiger, MA, RHIA, CCS, CRC, with bonus insights and analysis from Dr. James Kennedy.
RACmonitor is proud to welcome back Dr. Ronald Hirsch, one of his most requested webcasts. In this highly anticipated session, Dr. Hirsch will break down the complex Two Midnight Rule Medicare regulations, translating them into clear, actionable guidance. He’ll walk you through the basics of the rule, offer expert interpretation, and apply the rule to real-world clinical scenarios—so you leave with greater clarity, confidence, and the tools to ensure compliance.
Bring your questions and join the conversation during this open forum series, live every Wednesday at 10 a.m. EST from June 11–July 30. Hosted by Chuck Buck, these fast-paced 30-minute sessions connect you directly with top healthcare experts tackling today’s most urgent compliance and policy issues.
Fraud convictions don’t just punish a few bad claims; they can wipe out years of reimbursements. Don’t wait for an audit to learn the rules. Join Frank Cohen, MPA, for a live Q&A on spotting red flags, avoiding liability, and protecting your practice. Register now and bring your questions!
Substance abuse is everywhere. It’s a complicated diagnosis with wide-ranging implications well beyond acute care. The face of addiction continues to change so it’s important to remember not just the addict but the spectrum of extended victims and the other social determinants and legal ramifications. Join John K. Hall, MD, JD, MBA, FCLM, FRCPC, for a critical Q&A on navigating substance abuse in 2025. Register today and be a part of the conversation!
Copyright © 2025 ICD10monitor. Powered by MedLearn Media.
CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 2 with code CYBER24
